| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Service de Pneumologie et Réanimation, Hôpital Laënnec, Paris, France
2 From the Service de Cardiologie, Hôpital Trousseau, Tours, Paris, France
3 From the Service de Pneumologie et Réanimation, Hôpital Antoine Beclére, Clamart, Paris, France
Four centers participated in a double-blind study in which 53 patients with angiographically documented acute massive pulmonary embolism (baseline Miller index 
17/34 and mean pulmonary artery pressure 20 mm Hg) were randomly assigned to treatment with either 0.6 mg/kg bolus injection of alteplase over 15 min with a maximum dose of 50 mg (bolus group; n=36), or 100 mg of alteplase over 2 h (2-h group; n=17). The primary objective was to compare the rapidity of resolution of pulmonary embolism as judged by the change in total pulmonary resistance (TPR) over the initial first hour. Further objectives were to evaluate the changes in TPR over the next 11 h and the degree of lung scan resolution at 20 to 28 h. At 1 h, TPR decreased by 29±17 percent in the bolus group and by 36±16 percent in the 2-h group (mean ± SD; p=0.19). Continuous monitoring of TPR revealed that this variable improved in both groups without significant intergroup differences over the 12-h study period, although TPR decreased initially faster in the 2-h group. At 20 to 28 h, the absolute improvements in the lung scan perfusion defect were 14±12 percent in the bolus group compared with 13±9 percent in the 2-h group, with no significant intergroup differences. Major bleeding occurred in one patient of the 2-h group (6 percent) and in three patients of the bolus group (8 percent) (p>0.5). Four patients (three from the bolus group and one from the 2-h group) may have experienced recurrent pulmonary embolism during the hospital stay. Neither death nor intracranial bleeding occurred.
Key Words: alteplase • pulmonary embolism • thrombolysis
Submitted on November 2, 1993
Accepted on March 24, 1994
This article has been cited by other articles:
|
|
 |
|
  D. J. Perlroth, G. D. Sanders, and M. K. Gould Effectiveness and Cost-effectiveness of Thrombolysis in Submassive Pulmonary Embolism Arch Intern Med, January 8, 2007; 167(1): 74 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Capstick and M. T. Henry Efficacy of thrombolytic agents in the treatment of pulmonary embolism Eur. Respir. J., November 1, 2005; 26(5): 864 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Harris and S Meek When should we thrombolyse patients with pulmonary embolism? A systematic review of the literature Emerg. Med. J., November 1, 2005; 22(11): 766 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Meneveau, L. P. Ming, M. F. Seronde, N. Mersin, F. Schiele, F. Caulfield, Y. Bernard, and J.-P. Bassand In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy Eur. Heart J., August 1, 2003; 24(15): 1447 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Wood Major Pulmonary Embolism : Review of a Pathophysiologic Approach to the Golden Hour of Hemodynamically Significant Pulmonary Embolism Chest, March 1, 2002; 121(3): 877 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Arcasoy and J. W. Kreit Thrombolytic Therapy of Pulmonary Embolism: A Comprehensive Review of Current Evidence Chest, June 1, 1999; 115(6): 1695 - 1707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Venuta, E. A. Rendina, T. De Giacomo, and G. F. Coloni Catheter Fragmentation of Pulmonary Emboli Chest, June 1, 1999; 115(6): 1759 - 1759. [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ginsberg Management of Venous Thromboembolism N. Engl. J. Med., December 12, 1996; 335(24): 1816 - 1829. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
